Lupin Announces European Launch of Ranibizumab Biosimilar Ranluspec

manufacturing-news
Image Courtesy: Pixabay

Global pharmaceutical company Lupin Limited (Lupin) has announced the European launch of Ranluspec™, its biosimilar Ranibizumab, by its commercial partner Sandoz. The product is now available across Europe, excluding Germany, following approval by the European Commission in vial and pre-filled syringe presentations.

The launch marks a step in expanding access to biologic treatment options for patients with retinal diseases. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A).

Ranluspec™ is indicated for the treatment of several retinal and choroidal vascular conditions, including neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy and choroidal neovascularisation.

The European launch strengthens Lupin’s presence in the biosimilars segment and supports its strategy of expanding access to biologic medicines across international markets. Through its partnership with Sandoz, the company aims to make the treatment available to patients across the region.

Commenting on the launch, Thierry Volle, President, EMEA and Emerging Markets, Lupin, said, “The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region.”

Dr. Cyrus Karkaria, President – Biotech Business, Lupin, said, “The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems.”

The launch reflects Lupin’s continued focus on strengthening its biotechnology portfolio and expanding its presence in global markets through strategic commercial partnerships. The company’s capabilities in biologics research and manufacturing underpin its efforts to develop and commercialise biosimilar products.

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in more than 100 markets. Its portfolio includes branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients. The company has a strong presence in India and the United States across therapeutic areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women’s health.

Lupin operates 15 manufacturing facilities and six research centres globally, supported by a workforce of more than 26,000 professionals. Through its subsidiaries, including Lupin Diagnostics, Lupin Digital Health and Lupin Manufacturing Solutions, the company continues to focus on improving patient health outcomes.